← Leaderboards
Brett E Crawford
Zacharon Pharmaceuticals, Inc.
$3,953,297
Attributed
$5,294,055
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,294,055 · 9
By mechanism
R44$3,629,671 · 2
R43$1,414,384 · 5
R21$250,000 · 2
Top collaborators
- Charles Alexander Glass4 shared
Most similar at Zacharon Pharmaceuticals, Inc.
Same institution · by research overlap
- Charles Alexander Glass$1,651,872
- Jillian R Brown$1,377,386
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeInhibitor/AntagonistSmall Business Innovation Research GrantAnalogProgramsBaseSeriesLeadHigh Throughput ScreeningCollectionPharmaceutical PreparationsCellsIn VivoDesignIn VitroStructure-Activity RelationshipClinical ResearchHereditary DiseaseSamplingDoseLinkEnzyme DeficiencyLibrariesLipids
Grant awards (13)
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,781
R44 · FY2012 · NS · contact PI
Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI$335,739
R43 · FY2012 · NS · contact PI
Development of a Small Molecule Therapy for Metachromatic Leukodystrophy$296,236
R43 · FY2012 · NS · contact PI
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,327
R44 · FY2011 · NS · contact PI
A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases$342,896
R43 · FY2011 · NS · contact PI
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$339,513
R43 · FY2010 · NS · contact PI
Development of Novel Inhibitors of Ganglioside Biosynthesis$175,000
R44 · FY2010 · CA · contact PI
Development of Novel Inhibitors of Ganglioside Biosynthesis$106,461
R44 · FY2010 · CA · contact PI
Development of Novel Inhibitors of Ganglioside Biosynthesis$652,045
R44 · FY2009 · CA · contact PI
Development of Novel Inhibitors of Ganglioside Biosynthesis$697,057
R44 · FY2008 · CA · contact PI
Development of cell-based assays for discovery of GIcNAc-TV inhibitors.$125,000
R21 · FY2006 · NS · contact PI
Development of a cell-based screen for inhibitors of ganglioside biosynthesis$100,000
R43 · FY2006 · CA · contact PI
Cell-Based Screen-Inhibitors of Mucin-Type O-Linked(RMI)$125,000
R21 · FY2005 · NS